{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:55Z","timestamp":1740107455149,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["20K07150"],"award-info":[{"award-number":["20K07150"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04729-6","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:47:10Z","timestamp":1734626830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer"],"prefix":"10.1007","volume":"95","author":[{"given":"Kazuma","family":"Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuji","family":"Nagahama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminori","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"17","key":"4729_CR1","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T et al (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14(17):5459\u20135465. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5270","journal-title":"Clin Cancer Res"},{"key":"4729_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y et al (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664\u2013671. https:\/\/doi.org\/10.1002\/ijc.23131","journal-title":"Int J Cancer"},{"key":"4729_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","volume":"340","author":"K Okamoto","year":"2013","unstructured":"Okamoto K, Kodama K, Takase K et al (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340:97\u2013103. https:\/\/doi.org\/10.1016\/j.canlet.2013.07.007","journal-title":"Cancer Lett"},{"key":"4729_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T et al (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6:18. https:\/\/doi.org\/10.1186\/2045-824X-6-18","journal-title":"Vasc Cell"},{"issue":"7","key":"4729_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N Engl J Med"},{"issue":"12","key":"4729_CR6","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/cas.12826","volume":"106","author":"N Kiyota","year":"2015","unstructured":"Kiyota N, Schlumberger M, Muro K et al (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106(12):1714\u20131721. https:\/\/doi.org\/10.1111\/cas.12826","journal-title":"Cancer Sci"},{"issue":"7","key":"4729_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/fon-2018-0557","volume":"15","author":"S Takahashi","year":"2019","unstructured":"Takahashi S, Kiyota N, Yamazaki T et al (2019) A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 15(7):717\u2013726. https:\/\/doi.org\/10.2217\/fon-2018-0557","journal-title":"Future Oncol"},{"key":"4729_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM et al (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102:765\u2013776. https:\/\/doi.org\/10.1002\/cpt.787","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"4729_CR9","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","volume":"62","author":"MBA van der Kleij","year":"2023","unstructured":"van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ et al (2023) Therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacokinet 62(10):1333\u20131364. https:\/\/doi.org\/10.1007\/s40262-023-01293-9","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4729_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","volume":"36","author":"M Nagahama","year":"2019","unstructured":"Nagahama M, Ozeki T, Suzuki A et al (2019) Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol 36(5):39. https:\/\/doi.org\/10.1007\/s12032-019-1263-3","journal-title":"Med Oncol"},{"key":"4729_CR11","unstructured":"LENVIMA (Lenvatinib) (2015) Drug interview form (Package insert). Eisai Co., Ltd., Tokyo, Japan"},{"key":"4729_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ctrv.2018.06.019","volume":"69","author":"J Capdevila","year":"2018","unstructured":"Capdevila J, Newbold K, Licitra L et al (2018) Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev 69:164\u2013176. https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.019","journal-title":"Cancer Treat Rev"},{"issue":"Pt 1","key":"4729_CR13","doi-asserted-by":"publisher","first-page":"124996","DOI":"10.1016\/j.talanta.2023.124996","volume":"266","author":"Z Fang","year":"2024","unstructured":"Fang Z, Zhang H, Guo J, Guo J (2024) Overview of therapeutic drug monitoring and clinical practice. Talanta 266(Pt 1):124996. https:\/\/doi.org\/10.1016\/j.talanta.2023.124996","journal-title":"Talanta"},{"issue":"11","key":"4729_CR14","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1210\/jc.2015-3989","volume":"101","author":"B Robinson","year":"2016","unstructured":"Robinson B, Schlumberger M, Wirth LJ et al (2016) Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 101(11):4103\u20134109. https:\/\/doi.org\/10.1210\/jc.2015-3989","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4729_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/clinem\/dgab731","volume":"107","author":"MS Brose","year":"2022","unstructured":"Brose MS, Panaseykin Y, Konda B et al (2022) A randomized study of lenvatinib 18\u00a0mg vs 24\u00a0mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 107(3):776\u2013787. https:\/\/doi.org\/10.1210\/clinem\/dgab731","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"4729_CR16","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","volume":"35","author":"MS Brose","year":"2017","unstructured":"Brose MS, Worden FP, Newbold KL et al (2017) Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III select trial. J Clin Oncol 35(23):2692\u20132699. https:\/\/doi.org\/10.1200\/JCO.2016.71.6472","journal-title":"J Clin Oncol"},{"issue":"11","key":"4729_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5414\/CP204440","volume":"61","author":"Y Wei","year":"2023","unstructured":"Wei Y, Yu Y, Zhang W et al (2023) Effects of diet and gender on the pharmacokinetics of oral lenvatinib: a clinical trial in healthy Chinese participants. Int J Clin Pharmacol Ther 61(11):475\u2013481. https:\/\/doi.org\/10.5414\/CP204440","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"4729_CR18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/jcph.2103","volume":"62","author":"Y Hu","year":"2022","unstructured":"Hu Y, Chen R, Ye Z et al (2022) Population pharmacokinetic modeling of lenvatinib in Chinese patients with advanced hepatocellular carcinoma using real-world data. J Clin Pharmacol 62(12):1507\u20131517. https:\/\/doi.org\/10.1002\/jcph.2103","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4729_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000504604","volume":"9","author":"H Uojima","year":"2020","unstructured":"Uojima H, Chuma M, Tanaka Y et al (2020) Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib. Liver Cancer 9(2):193\u2013206. https:\/\/doi.org\/10.1159\/000504604","journal-title":"Liver Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04729-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:03:30Z","timestamp":1734627810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04729-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4729"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04729-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest.\u00a0The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the ethical standards of the Declaration of Helsinki and its subsequent amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Signed informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"8"}}